Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jul;15(4):539-551.
doi: 10.1111/irv.12850. Epub 2021 Mar 25.

The immunogenicity and safety of respiratory syncytial virus vaccines in development: A systematic review

Jing Shan  1   2 , Philip N Britton  2   3 , Catherine L King  4 , Robert Booy  2
Affiliations
Review

The immunogenicity and safety of respiratory syncytial virus vaccines in development: A systematic review

Jing Shan et al. Influenza Other Respir Viruses. 2021 Jul.

Abstract

Background: Respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory infection globally. There are vaccine candidates in development, but a systematic review on immunogenicity and safety of vaccine is lacking.

Methods: This systematic review of RSV vaccine clinical trials was undertaken using four databases. Searches were conducted using both controlled vocabulary terms such as "Respiratory Syncytial Virus, Human," "Respiratory Syncytial Virus Infections," "Respiratory Syncytial Virus Vaccines," "Immunization," "Immunization Programs" and "Vaccines" and corresponding text word terms. The included studies were limited to clinical trials published from January 2000 to 31 December 2020. RSV infection case was defined as RSV-associated medically attended acute respiratory illness (MAARI) or RSV infection by serologically confirmed test (Western blot) during the RSV surveillance period. We calculated the relative risk of each vaccine trial with RSV infection case.

Results: Of 6306 publications, 38 were included and data were extracted covering four major types of RSV vaccine candidates, these being live-attenuated/chimeric (n = 14), recombinant-vector (n = 6), subunit (n = 12) and nanoparticle vaccines (n = 6). For RSV infection cases, nine trials were involved and none of them showed a vaccine-related increased MAARI during RSV surveillance season.

Conclusion: LID ∆M2-2, MEDI M2-2, RSVcps2 and LID/∆M2-2 /1030s (live-attenuated) were considered the most promising vaccine candidates in infant and children. In the elderly, a nanoparticle F vaccine candidate and Ad26.RSV.preF were considered as two potential effective vaccines. A promising maternal vaccine candidate is still lacking.

Keywords: RSV promising vaccine; clinical trial; respiratory syncytial virus vaccine; safety and immunogenicity.

PubMed Disclaimer

Conflict of interest statement

Professor Robert Booy: I work with all major manufacturers of vaccines in an advisory capacity, as a researcher on vaccines, as a presenter of academic information at conferences and also occasionally as an Advisory Board member. I receive support to travel and attend such conferences and meetings from the various pharmaceutical companies. On occasions, I also receive an honorarium which is paid direct to my institution. Any funding received is directed to a research account at The University of Sydney and is not personally accepted by myself. Other authors have no conflicts of interest.

Figures

FIGURE 1
FIGURE 1
PRISMA flow chart
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Checchia PA, Nalysnyk L, Fernandes AW, et al. Mortality and morbidity among infants at high risk for severe respiratory syncytial virus infection receiving prophylaxis with palivizumab: a systematic literature review and meta‐analysis. Pediatr Crit Care Med. 2011;12(5):580‐588. - PubMed
    1. Falsey AR, Walsh EE. Respiratory syncytial virus infection in adults. Clin Microbiol Rev. 2000;13(3):371‐384. - PMC - PubMed
    1. Shi T, McAllister DA, O'Brien KL, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet. 2017;390(10098):946‐958. - PMC - PubMed
    1. Falsey AR, Cunningham CK, Barker WH, et al. Respiratory syncytial virus and influenza A infections in the hospitalized elderly. J Infect Dis. 1995;172(2):389‐394. - PubMed
    1. Dowell SF, Anderson LJ, Gary HE Jr, et al. Respiratory syncytial virus is an important cause of community‐acquired lower respiratory infection among hospitalized adults. J Infect Dis. 1996;174(3):456‐462. - PubMed

Substances

LinkOut - more resources